Minerva Biotechnologies develops cell therapy and antibodies to treat cancer, focusing on cancer immunotherapies that target solid tumors and prevent cancer metastasis. Founded in 1999 in Waltham, United States, the company has raised $18.9M in early stage funding from investors including HHS and Springboard Enterprises. Developer of cell therapy and antibodies to treat cancer. The company develops cancer immunotherapies to target solid tumors and to prevent cancer metastasis. The company operates in the nanotechnology space. Founded in 1999, headquartered in Waltham, United States. The team comprises 17 (Jun 30, 2026) employees. Backed by investors including HHS, Springboard Enterprises. Minerva Biotechnologies is recognized as a minicorn..
← All startups
Minerva Biotechnologies
Early StageMinerva Biotechnologies develops cell therapy and antibodies to treat cancer, focusing on cancer immunotherapies that target solid tumors and prevent cancer metastasis. Founded in 1999 in Waltham, United States, the company has raised $18.9M in early stage funding from investors including HHS and Springboard Enterprises. Developer of cell therapy and antibodies to treat cancer. The company develops cancer…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,
Oncology > Drugs > Breast Cancer
Team background
College Wise > Harvard University
Institutional investors
HHSSpringboard Enterprises
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.
Similar startups
Raising like Minerva Biotechnologies?
Analyze your pitch deck before your next raise.
Analyze My Deck →